Metagenomi Therapeutics Return on Investment 2022-2025 | MGX
Current and historical return on investment (ROI) values for Metagenomi Therapeutics (MGX) over the last 10 years.
| Metagenomi Therapeutics ROI - Return on Investment Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | LT Investments & Debt | Return on Investment |
| 2025-12-31 | $-0.10B | 0.00% | |
| 2025-09-30 | $-0.09B | 0.00% | |
| 2025-06-30 | $-0.09B | 0.00% | |
| 2025-03-31 | $-0.09B | 0.00% | |
| 2024-12-31 | $-0.09B | 0.00% | |
| 2024-09-30 | $-0.09B | 0.00% | |
| 2024-06-30 | $-0.09B | 0.00% | |
| 2024-03-31 | $-0.09B | 0.00% | |
| 2023-12-31 | $-0.08B | 0.00% | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.055B | $0.052B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $39.071B | 12.09 |
| BridgeBio Pharma (BBIO) | United States | $14.501B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.806B | 18.36 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.915B | 23.87 |
| Bausch Health Cos (BHC) | Canada | $2.222B | 1.58 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.310B | 9.44 |
| Taysha Gene Therapies (TSHA) | United States | $1.246B | 0.00 |
| Personalis (PSNL) | United States | $0.729B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.422B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.187B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |